ערך בספרים למניה: Sophia Genetics (SOPH)

The development of SOPHiA GENETICS SA (SOPH) relies on the proliferation of cloud-based genome analysis and strict adherence to data privacy standards. Its competitive advantage is growing through the network effect, as the expansion of the clinic base establishes the software as an industry standard. Today, the company is recognized as a global leader in AI cancer diagnostics, with the indicator standing at 0.98. The share price history below clearly illustrates the price action of this precision medicine tech giant.

The market values SOPHiA GENETICS SA (SOPH) through the lens of scaling cloud infrastructure in Switzerland and the US, where asset value correlates directly with technological superiority in precision medicine. Analyzing the book value per share chart, an investor can see the residual equity per share, which allows for the determination of the real value of net assets and an assessment of the company's financial stability.